Tamara Ruggles’ Post

View profile for Tamara Ruggles, graphic

Owner of The Deprescribing Clinic | Consultant Pharmacist | Podcast Host | Speaker

Did you know deutetrabenazine (Austedo) used for tardive dyskinesia and Huntington disease-associated chorea has PGx guided dosing? From the drug label: "In patients who are poor CYP2D6 metabolizers, the total daily dosage of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg)." The same max dose recommendations hold true if your patient is taking deutetrabenazine with strong CYP2D6 inhibitors such as paroxetine, fluoxetine, and bupropion. #pharmacogenomics #pharmacist

DeLon Canterbury, PharmD, BCGP

TEDx Speaker | CEO of GeriatRx, Inc. | Certified Community Pharmacogenomics (PGx) Consultant, Deprescribing Coach and Implementation Strategist, Top 50 Most Influential Pharmacists 2022, The Deprescribing Pharmacist

3mo

Unfortunately had a case with this who was intermediate and had significant changes in increases suicidal ideation, while taking it with a med that genetically interacted with it

Arisha Munir, Pharm.D

Senior Pharmacist | Antimicrobial Stewardship Certified | Primary Care /Ambulatory Care| UpToDate Certified Trainer | TPN Expert

3mo

Very informative

Like
Reply
Sean Rana

VP Marketing at RxOnWeb

3mo

That's great to know! It's important for healthcare providers to be aware of the pharmacogenetic information associated with medications like deutetrabenazine. By considering a patient's genetic makeup, we can tailor treatment plans to optimize efficacy and minimize side effects.

See more comments

To view or add a comment, sign in

Explore topics